Monitor the final pricing and size of both the equity and convertible note offerings when announced. The concurrent convertible note offering introduces potential hedging activity that could pressure the stock. The positive OPUS-1 data provides some fundamental support, but the dilution and debt overhang from these offerings is the dominant near-term factor.
Price Chart
Executive Summary
Vaxcyte is conducting a dilutive common stock and pre-funded warrant offering (424B5) concurrently with a convertible note offering, with all key terms (size, price, proceeds) left as placeholders. The filing follows positive Phase 3 OPUS-1 data for VAX-31 announced on October 5, 2026. The company expects ~$2.3B in cash as of September 30, 2026. The offerings increase share count and add debt, creating dilution and overhang.
Key Facts
- Preliminary prospectus supplement for an offering of common stock and pre-funded warrants; all dollar amounts and share counts are placeholder amounts (e.g., $[●], shares [●]).
- Concurrent offering of % convertible senior notes due 2032 in an undisclosed principal amount, with an undisclosed over-allotment option.
- Last reported sale price of PCVX on October 5, 2026 was $73.82 per share.
- Company expects cash, cash equivalents and investments as of September 30, 2026 to be approximately $2.3 billion.
- Net tangible book value as of June 30, 2026 was $2,648 million, or $18.29 per share.
- Existing stockholders will suffer immediate and substantial dilution; the filing warns of 'immediate and substantial dilution' for new investors.
- Underwriters granted a 30-day option to underwriters to purchase additional shares of common stock (amount undisclosed).
- The company has a Sales Agreement with Leerink Partners LLC to sell up to $500.0 million of common stock, with no sales for 30 days from this prospectus supplement.
- VAX-31 Phase 3 OPUS-1 trial met all prespecified co-primary immunogenicity endpoints; positive topline results announced October 5, 2026.
Financial Impact
Dilutive equity and convertible note offerings of undisclosed size; company had $2.5B in cash and equivalents as of June 30, 2026 and expects ~$2.3B as of September 30, 2026.
Risk Factors
- Immediate and substantial dilution to existing stockholders from the equity offering.
- Potential downward pressure from convertible note arbitrage hedging (short selling) by note investors.
- Management has broad discretion over use of proceeds, which may not enhance shareholder value.
- No public market for pre-funded warrants, limiting liquidity for those securities.
- Future dilution from exercise of outstanding options, RSUs, pre-funded warrants, and conversion of convertible notes.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-414772 |
| Document: 0001193125-26-414772-index-headers.html | 0001193125-26-414772 |
| Document: 0001193125-26-414772-index.html | 0001193125-26-414772 |
| Document: 0001193125-26-414772.txt | 0001193125-26-414772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $60.59 (+14.24%) |
Oct 8, 2026 18d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.59 (+15.12%) |
Oct 8, 2026 18d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.59 (+15.12%) |
Oct 5, 2026 21d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $60.59 (−9.16%) |
Oct 5, 2026 21d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $60.59 (+9.16%) |
Oct 5, 2026 22d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.59 (−17.92%) |
Oct 5, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.59 (−17.92%) |
Oct 4, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.59 (−17.92%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $60.59 (+2.89%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $60.59 (−0.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers